{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:44:44Z","timestamp":1769442284038,"version":"3.49.0"},"reference-count":18,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["dir"],"DOI":"10.4274\/dir.2024.242929","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T01:55:32Z","timestamp":1732499732000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the prognostic impact of inflammatory markers on treatment outcomes in patients with intrahepatic cholangiocarcinoma undergoing radioembolization"],"prefix":"10.4274","author":[{"given":"Sinan","family":"Sozutok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferhat Can","family":"Pi\u015fkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcseyin Tu\u011fsan","family":"Ball\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berkay","family":"Dik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2023;9:107064. [CrossRef]","DOI":"10.1016\/j.ejso.2023.107064"},{"key":"ref1","unstructured":"2. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016:13(5):261-280. [CrossRef]"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428-444. [CrossRef]","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. Hepat Oncol. 2017;4(4):99-109. [CrossRef]","DOI":"10.2217\/hep-2017-0014"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251-1278. Erratum in: J Vasc Interv Radiol. 2006;17(10):1594. [CrossRef]","DOI":"10.1097\/01.RVI.0000233785.75257.9A"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Elvevi A, Laffusa A, Elisei F, et al. Any role for transarterial radioembolization in unresectable intrahepatic cholangiocarcinoma in the era of advanced systemic therapies? World J Hepatol. 2023;15(12):1284-1293. [CrossRef]","DOI":"10.4254\/wjh.v15.i12.1284"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7(1):16717. [CrossRef]","DOI":"10.1038\/s41598-017-16955-5"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009:30(7):1073-1081. [CrossRef]","DOI":"10.1093\/carcin\/bgp127"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Young S, Rubin N, D'Souza D, et al. Inflammatory scores: correlation with clinical outcomes in hepatocellular carcinoma patients undergoing transarterial radioembolization. Cardiovasc Intervent Radiol. 2022;45(4):461-475. [CrossRef]","DOI":"10.1007\/s00270-022-03080-8"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. \u00d6cal O, Kup\u010dinskas J, Morkunas E, et al. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Res. 2021;11(1):51. [CrossRef]","DOI":"10.1186\/s13550-021-00791-w"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Filippi L, Di Costanzo GG, Tortora R, et al. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. Nucl Med Commun. 2020;41(1):78-86. [CrossRef]","DOI":"10.1097\/MNM.0000000000001123"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF. Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol. 2013;36(3):613-622. [CrossRef]","DOI":"10.1007\/s00270-013-0600-8"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60. [CrossRef]","DOI":"10.1055\/s-0030-1247132"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Yang Z, Zhang D, Zeng H, et al. Inflammation-based scores predict responses to PD-1 Inhibitor treatment in intrahepatic cholangiocarcinoma. J Inflamm Res. 2022;15:5721-5731. [CrossRef]","DOI":"10.2147\/JIR.S385921"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Yu L, Zheng S, Yang J, Fu Z, Zhu X, Su K. Association between the systemic immune inflammation index and recurrence or metastasis after interventional therapy in patients with primary liver cancer- a retrospective cohort study. J Gastrointest Oncol. 2023;14(2):780-788. [CrossRef]","DOI":"10.21037\/jgo-23-104"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Ren A, Li Z, Cheng P, Zhang X, Deng R, Ma Y. Systemic immune-inflammation index is a prognostic predictor in patients with intrahepatic cholangiocarcinoma undergoing liver transplantation. Mediators Inflamm. 2021;2021:6656996. [CrossRef]","DOI":"10.1155\/2021\/6656996"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Li J, Gao L, Liu T, Feng D. Association of systemic inflammation index with survival in patients with advanced perihilar cholangiocarcinoma treated with interventional therapy. Front Oncol. 2022;12:1038759. [CrossRef]","DOI":"10.3389\/fonc.2022.1038759"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Li H, Wang JJ, Zhang M, et al. Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection. World J Gastrointest Oncol. 2020;12(4):467-482. [CrossRef]","DOI":"10.4251\/wjgo.v12.i4.467"}],"container-title":["Diagnostic and Interventional Radiology"],"original-title":[],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:24:12Z","timestamp":1753446252000},"score":1,"resource":{"primary":{"URL":"https:\/\/dirjournal.org\/articles\/doi\/dir.2024.242929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":18,"URL":"https:\/\/doi.org\/10.4274\/dir.2024.242929","relation":{},"ISSN":["1305-3825","1305-3612"],"issn-type":[{"value":"1305-3825","type":"print"},{"value":"1305-3612","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}